Loading
TAR-200 is a small pretzel-shaped device placed in the bladder that releases gemcitabine for three weeks at a time. It was approved in 2025 for early bladder cancer that no longer responds to BCG.
TAR-200 is a small pretzel-shaped osmotic mini-tablet system placed in the bladder via a urinary catheter in the clinic; it releases gemcitabine continuously into urine, giving sustained local exposure without systemic levels. The FDA approved it on 9 September 2025 for BCG-unresponsive NMIBC with carcinoma in situ on the basis of SunRISe-1, where monotherapy produced a complete response in 82% of patients and 51% remained in CR at 1 year. Urinary tract infection and dysuria were the common side effects, with grade 3 or higher treatment-related events in 12%. Phase 3 trials cover BCG-naive NMIBC (SunRISe-3) and muscle-invasive disease (SunRISe-4 with cetrelimab, SunRISe-2 versus chemoradiation); Johnson & Johnson develops it after acquiring Taris. It offers slow-release chemotherapy from inside the bladder as an alternative to bladder removal when BCG fails.
Osmotic mini-tablet system continuously releases gemcitabine into urine, achieving sustained local exposure without systemic levels.
1.Device inserted through a urinary placement catheter and coils in the bladder
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Intravesical drug-releasing system placed in the urology clinic; approved 2025 and newly assigned coding, so check the local Medicare contractor.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. New product; expect plan policies to lag the approval by several months.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: TAR-200 (gemcitabine intravesical system). Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
FDA approval of Inlexzo source
| Region | Year | Indication |
|---|---|---|
| US | 2025 | BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumours |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Urinary tract infection | 24% | - |
| Dysuria | 22% | - |
| Pollakiuria | 20% | - |
| Grade 3+ treatment-related | - | 12% |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Gemcitabine intravesical system" OR ABSTRACT:"Gemcitabine intravesical system" OR TITLE:"TAR-200" OR ABSTRACT:"TAR-200" OR TITLE:"Inlexzo" OR ABSTRACT:"Inlexzo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gemcitabine intravesical system (TAR-200), not a curated reading list.
Shares BCG-unresponsive, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares BCG-unresponsive, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.